|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Veno occlusive disease: Update on clinical management显示文摘Hepatic veno-occlusive disease is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, due to sinusoidal congestion which can be caused by alkaloid ingestion, but the most frequent cause is haematopoietic stem cell transplantation (STC) and is also seen after solid organ transplantation. The incidence of veno occlusive disease (VOD) after STC ranges from 0 to 70%, but is decreasing. Survival is good when VOD is a mild form, but when it is severe and associated with an increase of hepatic venous pressure gradient > 20 mmHg, and mortality is about 90%. Prevention remains the best therapeutic strategy, by using non-myeloablative conditioning regimens before STC. Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-fibrinolytic and antithrombotic properties, is the most effective therapy; decompression of the sinusoids by a transjugular intrahepatic portosystemic shunt (TIPS) can be tried, especially to treat VOD after liver transplantation and when multiorgan failure (MOF) is not present. Liver transplantation can be the last option, but can not be considered a standard rescue therapy, because usually the concomitant presence of multiorgan failure contraindicates this procedure. | M Senzolo G Germani E Cholongitas P Burra AK Burroughs | 2007 | World Journal of Gastroenterology2007，13，29： | 19 |
| 2 | New insights into the coagulopathy of liver disease and liver transplantation显示文摘The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery. | M Senzolo P Burra E Cholongitas AK Burroughs | 2006 | World Journal of Gastroenterology2006，12，48： | 12 |
| 3 | P 53 and PCNA in Non Hodgkin's lymphoma-an immunohistochemical evaluation显示文摘 | Shanthi P Krishnan KB | 2000 | Indian J Pathol Microbiol2000，43，1： | 1 |
| 4 | Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2 hr post-dose levels (C2)显示文摘 | LEVY G BURRA P CAVALLARI A | 2002 | Transplantation2002，73，6： | 1 |
| 5 | Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease 显示文摘 | ADAMS DH BURRA P HUBSCHER SG | 1994 | Hepatology1994，19，3： | 1 |
| 6 | Improved clinical outcomes for liver transplant recipients using cycloaporine monitoring based on 2-hr post-dose levels (C2)显示文摘 | levy G Burra P Cavallari A | 2002 | Transplantation2002，73，： | 1 |
| 7 | Randomized trim of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation显示文摘 | Naoumov N V Lopes A R Burra P | 2001 | J Hepatol2001，34，6： | 1 |
| 8 | Dynamic tests to study liver function显示文摘 | Burra P Masier A | 2004 | Eur Rev Med Pharmacol Sci2004，8，1： | 1 |
| 9 | Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered显示文摘 | Senzolo M Ferronato C Burra P | 2009 | Intern emerg med2009，4，2： | 1 |
| 10 | Evaluation of graft and recipient risk factors in liver transplantation显示文摘 | Burra P Martin ED Senzolo M | 2009 | Dig Liver Dis Suppl2009，3，4： | 1 |
| 11 | CD105 ( + ) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential显示文摘 | Conconi MT Burra P Di Liddo R | 2006 | Int J Mol Med2006，18，： | 1 |
| 12 | Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience显示文摘 | Burra P Targhetta S Pevere S | 2006 | Transplant Proc2006，38，4： | 1 |
| 13 | Systemic administration of a novel human umbilical cord mesenchymal stem ceils population accelerates the resolution of acute liver injury 显示文摘 | Burra P Arcidiacono D Bizzaro D | 2012 | BMC Gastroenterology2012，12，1： | 1 |
| 14 | Donor livers with steatosis are safe to use in hepatitis C virus - positive recipi-ents显示文摘 | BURRA P LORENO M RUSSO FP | 2009 | Liver Transpl2009，15，6： | 1 |
| 15 | beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients:a meta analysis显示文摘 | Senzolo M Cholongitas E Burra P | | 0，，： | 1 |
| 16 | Randomized trial of lamivudine versus hepatitis B immunoglobulin for longterm prophylaxis of hepatitis B recurrence after liver trans plantstion显示文摘 | Naournov N V Lopes A R Burra P | 2001 | J Hepatol2001，34，： | 1 |
| 17 | CD105+cells from Wharton's jelly show in vitro myogenic differentiative potential显示文摘 | Concni MT Burra P Di Liddo R | 2006 | Int J Mol Med2006，18，： | 1 |
| 18 | beta - Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta - analysis显示文摘 | SENZOLO M CHOLONGITAS E BURRA P | 2009 | Liver Int2009，29，8： | 1 |
| 19 | Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)显示文摘 | Levy G Burra P Cavallari A Duvoux C Lake J Mayer AD | 2002 | Transplantation2002，73，： | 1 |
| 20 | Quality of life following organ transplanta- tion 显示文摘 | Burra P Bona M | 2007 | Transplant International2007，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员